Advanced
Product
Solutions
Partners
Resources
Company
Toggle menu
Home
/
Waverley Pharma
Waverley Pharma
Overview
Locations
Financials
Operating Metrics
Human Capital
Key People
Competitors
Supplier Risk
Waverley Pharma
Stock Price
$0
2024-10-29
Market Capitalization
$810 K
2024-10-29
Revenue
$475 K
FY, 2024
Waverley Pharma Summary
Company Summary
Overview
Waverley Pharma is a biopharmaceutical company that researches, develops, and commercializes cancer therapeutics. It focuses on generic oncology injectable products.
Type
Public
Status
Active
Founded
2014
HQ
Winnipeg, CA
|
view all locations
Website
https://www.waverleypharma.com
Cybersecurity rating
Sectors
Healthcare
biotech
drug development
oncology
pharma
Homepage
Linkedin
Table of Contents
Key People
Locations
Financials
Competitors
Key People
Larry Thiessen,
President and Chief Executive Officer
Albert D. Friesen,
Director
P. Marcus Enns,
Director
Locations
View all
1 location detected
Winnipeg, MB
HQ
Canada
1250 Waverley St #4
Waverley Pharma Financials
Summary Financials
Revenue (Q3, 2025)
$C276.0K
Gross profit (Q3, 2025)
$C90.0K
Net income (Q3, 2025)
($C237.0K)
Cash (Q3, 2025)
$C68.0K
EBIT (Q3, 2025)
($C188.0K)
Enterprise value
$3.7M
Competitors and Similar Companies
Puma Biotechnology
Healthcare - Public
Progenics Pharmaceuticals
Healthcare - Subsidiary
Biocon
Healthcare - Public
RS Research
Healthcare - Private
Compare competitors
Footer menu
Contact us
Product
Intelligence Suite
Supplier Intelligence Platform
Craft Intelligence Portal
Craft API
Craft for Teams
Supplier Intelligence Platform
Craft Alerts
Craft N-Tier Mapping
Craft Risk Hub
Chrome extension
Solutions
Supplier Intelligence
Sales Intelligence
Aerospace and Defense
Resources
Resource center
Blog
Company
About
Careers
Contact
Terms of Service
Privacy Policy
Security
© Craft.co 2026
Share price data provided by IEX
Back
to top